ArticleFrontiers in immunology2026
Gut dysbiosis and systemic inflammation in elderly hypertensive patients with amnestic mild cognitive impairment.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Gut microbial dysbiosis has been linked to both high blood pressure and neurodegeneration, but its involvement in hypertensive patients with amnestic mild cognitive impairment (aMCI) has not been well characterized in this specific population. Methods: In this cross-sectional investigation, we enrolled 205 older Chinese adults: 52 healthy controls, 83 hypertensive individuals with normal cognition (HTN-CN), and 70 hypertensive subjects with aMCI (HTN-aMCI). Gut microbiota composition was profiled by 16S rRNA sequencing, and serum levels of 27 inflammatory mediators were quantified by multiplex immunoassay. Results: Compared to the HTN-CN and control groups, the HTN-aMCI group showed not only a greater richness of gut microbes but also a markedly segregated microbial community structure. The HTN-aMCI microbiota was characterized by significant depletion of short-chain fatty acid (SCFA)-producing genera ( Discussion: These findings indicate that hypertensive individuals with aMCI harbor a specific gut microbial dysbiosis marked by loss of SCFA producers, expansion of pathobionts, and disrupted microbial networks, which together associate with systemic inflammation and cognitive decline. Our results support the notion that targeting gut microbiota might represent a potential therapeutic avenue for hypertension-related cognitive impairment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.